-
公开(公告)号:EP4200286A1
公开(公告)日:2023-06-28
申请号:EP21769576.6
申请日:2021-08-18
IPC分类号: C07D277/34 , C07D417/06 , C07D263/44 , C07D413/06 , C07D417/10 , A61P1/16
-
公开(公告)号:EP4054568A1
公开(公告)日:2022-09-14
申请号:EP20884888.7
申请日:2020-11-06
发明人: COLCA, Gerard R. , DITTRICH, Howard C. , FARMER, Brian K. , COTTER, Gad , COTTER-DAVISON, Beth Anne
IPC分类号: A61K31/426 , A61P1/16 , A61P3/10 , C07D277/34 , C12Q1/52 , G01N33/72 , G16H50/20
-
公开(公告)号:EP3700893A1
公开(公告)日:2020-09-02
申请号:EP18795464.9
申请日:2018-10-24
发明人: HUETER, Ottmar, Franz , HOPPE, Mark , SMEJKAL, Tomas , DUMEUNIER, Raphael , FEDOU, Nicolas , GODINEAU, Edouard , WEGE, Philip , MAIENFISCH, Peter
IPC分类号: C07D277/32 , C07D277/34 , A01N43/78
-
公开(公告)号:EP2739609B1
公开(公告)日:2019-07-17
申请号:EP12745463.5
申请日:2012-08-02
申请人: Karo Pharma AB
发明人: CHENG, Aiping , GARG, Neeraj , KRÜGER, Lars , LÖFSTEDT, Joakim , KOCH, Eva , KOEHLER, Konrad , HAGBERG, Lars , NÖTEBERG, Daniel
IPC分类号: C07D213/58 , C07D215/12 , C07D217/14 , C07D231/12 , C07D233/64 , C07D235/16 , C07D261/08 , C07D277/30 , C07D277/34 , C07D307/54 , C07D307/68 , C07D307/87 , C07D317/60 , C07D333/20 , C07D409/10 , C07D413/10 , C07D295/155 , C07D207/327 , A61K31/155 , A61K31/381
-
公开(公告)号:EP2365969B1
公开(公告)日:2017-03-22
申请号:EP09796470.4
申请日:2009-11-19
申请人: Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. , Hadasit Medical Research Services and Development Ltd.
IPC分类号: C07D277/34 , C07D207/448 , A61K31/4015 , A61K31/426 , C08F8/14 , C08F8/30 , A61P31/00 , A01N43/78 , A01N43/36
CPC分类号: C07D277/34 , A01N37/32 , A01N43/50 , A01N43/76 , A01N43/78 , C07D207/448 , C08F220/14 , C08F220/56 , C08F222/40 , C08F228/06 , C08G65/33337 , C08G65/3348 , A01N43/653 , A01N2300/00
摘要: Novel agents exhibiting anti-biofilm formation activity while being non-cytotoxic are provided, as well as methods of using the same, either per se or conjugated to a polymer, for preventing and/or reducing the formation of microbial biofilms and/or for disrupting microbial biofilms. The novel agents described herein include thiazolidine-2,4-diones (TZDs), pyrrolidine-2,5-diones (PYDs), imidazolidine-2,4-diones or oxazolidine-2,4-diones, substituted by an alkyl having 7-20 carbon atoms in its backbone chain.
-
6.DÉRIVÉS DE THIAZOLIDINEDIONE, LEUR PRÉPARATION ET LEUR UTILISATION DANS LE TRAITEMENT DES CANCERS 有权
标题翻译: 噻唑烷二酮衍生物,生产和使用THEREOF IN癌症治疗公开(公告)号:EP2838899B1
公开(公告)日:2016-10-05
申请号:EP13701119.3
申请日:2013-01-25
发明人: BOISBRUN, Michel , CHAPLEUR, Yves , BORDESSA, Andrea , FLAMENT, Stéphane , GRILLIER-VUISSOZ, Isabelle , KUNTZ, Sandra
IPC分类号: C07D417/12 , C07D277/34 , C07D417/06 , C07D417/14 , C07D311/66 , A61K31/427 , A61P35/00
CPC分类号: C07D417/14 , C07D277/34 , C07D311/66 , C07D311/74 , C07D417/06 , C07D417/12
-
公开(公告)号:EP3010888A1
公开(公告)日:2016-04-27
申请号:EP14732165.7
申请日:2014-06-18
申请人: BASF SE
发明人: WINTER, Christian , RHEINHEIMER, Joachim , WOLF, Antje , TERTERYAN, Violeta , POONOTH, Manojkumar , WIEBE, Christine , KREMZOW-GRAW, Doris , RÖHL, Franz , ROHRER, Sebastian Georgios , WIEJA, Andy , ROSENBAUM, Claudia , GRAMMENOS, Wassilios
IPC分类号: C07D231/12 , C07D231/20 , C07D239/34 , C07D261/12 , C07D213/06 , C07D213/61 , C07D213/64 , C07D401/04 , C07D249/10 , C07D277/34 , A01N47/10 , A01N47/28 , C07C271/12 , C07C275/04 , C07C281/02
CPC分类号: C07D405/04 , A01N47/12 , A01N47/24 , A01N47/28 , C07C251/38 , C07C271/16 , C07C275/24 , C07C281/02 , C07D213/06 , C07D213/46 , C07D213/61 , C07D213/64 , C07D231/12 , C07D231/20 , C07D239/26 , C07D239/34 , C07D249/10 , C07D261/12 , C07D263/32 , C07D277/34 , C07D401/04
摘要: The present invention relates to novel strobilurine type compounds I, processes for preparing these compounds, a use of compounds of the formula I and/or their agriculturally useful salts for controlling phytopathogenic fungi, to compositions comprising at least one such compound, to plant health applications, and to seeds coated with at least one such compound.
摘要翻译: 本发明涉及新的嗜球果伞碱类化合物I,制备这些化合物的方法,式I化合物和/或其农业上有用的盐用于防治植物病原真菌的用途,含有至少一种这样的化合物的组合物,植物健康应用 以及用至少一种这样的化合物涂覆的种子。
-
8.N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR 有权
标题翻译: N-(2-芳基乙基)苄胺ALS 5-HT6受体antagoniste公开(公告)号:EP1859798B1
公开(公告)日:2015-12-30
申请号:EP07015058.6
申请日:2002-03-15
发明人: Chen, Zhaogen , Cohen, Michael Philip , Fisher, Matthew Joseph , Gillig, James Ronald , McCowan, Jefferson Ray , Miller, Shawn Christopher , Schaus, John Mehnert , Giethlen, Bruno
IPC分类号: A61K31/4045 , C07D209/16 , A61P25/18 , A61P25/28 , C07D403/12 , C07D401/12 , A61K31/4406 , A61K31/4409 , A61K31/506 , A61K31/4402 , C07C217/54 , C07C323/01 , C07C317/14 , C07D213/64 , C07D277/34 , C07D239/34 , C07D233/24 , C07D333/20 , C07D307/91 , C07D209/14
CPC分类号: C07C211/52 , C07C211/56 , C07C217/58 , C07C217/60 , C07C225/16 , C07C311/37 , C07C317/34 , C07C323/32 , C07D209/08 , C07D209/14 , C07D213/38 , C07D213/64 , C07D213/65 , C07D213/68 , C07D213/74 , C07D233/24 , C07D239/34 , C07D277/34 , C07D307/91 , C07D333/20 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/12 , C07D417/12 , C07F7/0812
-
公开(公告)号:EP2758380B1
公开(公告)日:2015-10-21
申请号:EP12766618.8
申请日:2012-09-17
发明人: GILLESPIE, Paul
IPC分类号: C07D277/34 , C07D277/38 , C07D417/04 , C07D417/08 , C07D417/12 , A61K31/425 , A61K31/427 , A61K31/4535 , A61K31/497 , A61K31/5377 , A61K31/4436 , A61K31/506 , A61P35/00
CPC分类号: C07D277/34 , C07D277/38 , C07D417/04 , C07D417/08 , C07D417/12
-
10.DÉRIVÉS DE THIAZOLIDINEDIONE, LEUR PRÉPARATION ET LEUR UTILISATION DANS LE TRAITEMENT DES CANCERS 有权
标题翻译: 噻唑烷二酮衍生物,生产和使用THEREOF IN癌症治疗公开(公告)号:EP2838899A1
公开(公告)日:2015-02-25
申请号:EP13701119.3
申请日:2013-01-25
发明人: BOISBRUN, Michel , CHAPLEUR, Yves , BORDESSA, Andrea , FLAMENT, Stéphane , GRILLIER-VUISSOZ, Isabelle , KUNTZ, Sandra
IPC分类号: C07D417/12 , C07D277/34 , C07D417/06 , C07D417/14 , C07D311/66 , A61K31/427 , A61P35/00
CPC分类号: C07D417/14 , C07D277/34 , C07D311/66 , C07D311/74 , C07D417/06 , C07D417/12
摘要: The present invention relates to thiazolidinedione derivatives, to the processes for preparing same and to the therapeutic use thereof for preventing or treating cancer, and more specifically breast cancer. These compounds are of formula (I) and exhibit, at a concentration of 100 µM, a hepatocyte viability preferably greater than 60%, preferably greater than 80% and more preferentially greater than 85%.
-
-
-
-
-
-
-
-
-